Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SEPN
3351
Septerna Inc
SEPN
$1.76B
| $1.06M | ﹤0.01% |
38,147
+8,045
| +27% | +$192K |
2024 Q4
4 quarters
|
|
3352
IBEX
IBEX
$579M
| $1.06M | ﹤0.01% |
27,771
+2,235
| +9% | +$82.7K |
2022 Q1
15 quarters
|
|
3353
Bowman Consulting
BWMN
$738M
| $1.06M | ﹤0.01% |
32,087
+1,872
| +6% | +$71K |
2022 Q3
13 quarters
|
|
|
GRDN
3354
Guardian Pharmacy Services
GRDN
$2.68B
| $1.06M | ﹤0.01% |
35,185
+7,212
| +26% | +$204K |
2024 Q3
5 quarters
|
|
3355
Neuropace
NPCE
$436M
| $1.06M | ﹤0.01% |
68,555
+3,560
| +5% | +$47.6K |
2022 Q1
15 quarters
|
|
3356
First Trust NASDAQ Cybersecurity ETF
CIBR
$17.4B
| $1.06M | ﹤0.01% |
14,792
+7,546
| +104% | +$565K |
2024 Q2
6 quarters
|
|
3357
CALL
Array Technologies
ARRY
$628M
| $1.05M | ﹤0.01% |
114,300
-150,000
| -57% | -$1.29M |
2025 Q2
2 quarters
|
|
|
MPT
3358
Medical Properties Trust
MPT
$1.95B
| $1.05M | ﹤0.01% |
210,354
+7,373
| +4% | +$38.4K |
2013 Q2
50 quarters
|
|
3359
Petco
WOOF
$627M
| $1.05M | ﹤0.01% |
373,854
+230,207
| +160% | +$745K |
2022 Q1
15 quarters
|
|
3360
Lightspeed Commerce
LSPD
$1.27B
| $1.05M | ﹤0.01% |
86,897
+73,657
| +556% | +$872K |
2022 Q1
15 quarters
|
|
|
INGM
3361
Ingram Micro Holding
INGM
$6.56B
| $1.05M | ﹤0.01% |
49,142
+48,831
| +15,701% | +$1.06M |
2024 Q4
4 quarters
|
|
3362
USCB Financial Holdings
USCB
$417M
| $1.05M | ﹤0.01% |
56,822
+5,577
| +11% | +$99.7K |
2022 Q2
14 quarters
|
|
3363
Pulmonx
LUNG
$78.6M
| $1.04M | ﹤0.01% |
472,251
+132,569
| +39% | +$249K |
2022 Q1
15 quarters
|
|
3364
PUT
AT&T
T
$167B
| $1.04M | ﹤0.01% |
42,000
| – | – |
2025 Q2
2 quarters
|
|
3365
Citizens
CIA
$179M
| $1.04M | ﹤0.01% |
215,908
+13,689
| +7% | +$75.4K |
2016 Q3
37 quarters
|
|
3366
Excelerate Energy
EE
$1.02B
| $1.04M | ﹤0.01% |
37,171
+3,389
| +10% | +$91.7K |
2022 Q2
14 quarters
|
|
|
CLDT
3367
Chatham Lodging
CLDT
$637M
| $1.04M | ﹤0.01% |
153,011
-136,041
| -47% | -$903K |
2013 Q2
50 quarters
|
|
|
SOMN
3368
The Southern Company 2025 Series A Corp Units
SOMN
| $1.04M | ﹤0.01% |
+20,687
| New | +$1.03M |
2025 Q4
0 quarters
|
|
3369
Graham Corp
GHM
$1.07B
| $1.04M | ﹤0.01% |
16,212
+350
| +2% | +$21.1K |
2023 Q3
9 quarters
|
|
3370
Hycroft Mining Holding Corp
HYMC
$1.74B
| $1.04M | ﹤0.01% |
43,638
+38,221
| +706% | +$423K |
2025 Q3
1 quarter
|
|
3371
Real REMAX Group Inc. Common Stock
REAX
$358M
| $1.04M | ﹤0.01% |
28,407
+8,173
| +40% | +$316K |
2024 Q1
7 quarters
|
|
3372
Tootsie Roll Industries
TR
$2.86B
| $1.04M | ﹤0.01% |
29,122
-9,454
| -25% | -$358K |
2013 Q2
50 quarters
|
|
3373
Forum Energy Technologies
FET
$954M
| $1.04M | ﹤0.01% |
28,023
-142
| -0.5% | -$4.41K |
2022 Q4
12 quarters
|
|
3374
Cable One
CABO
$69.3M
| $1.03M | ﹤0.01% |
9,112
+921
| +11% | +$126K |
2015 Q3
41 quarters
|
|
3375
MetroCity Bankshares
MCBS
$1.01B
| $1.03M | ﹤0.01% |
38,710
+6,194
| +19% | +$165K |
2019 Q4
24 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.